Released Nov 12, 2024, before the open
10-Q filed Nov 12, 2024, 43 days after period end · 0001576885-24-000098
Q3 2024 · 10-Q
Revenue—
Net Income-$29.77M-$29.77M N/M vs Q3 2023N/M vs Q2 2024
EPS Diluted-$0.50-$0.50 N/M vs Q3 2023N/M vs Q2 2024
Operating Income-$32,265,000N/M
Operating Cash Flowderived-$24,596,000N/M
Free Cash Flowderived-$24,596,000N/M
What the release said
The release
Same quarter
| Metric | Q3 2024 | Q3 2023 | Q3 2022 | Q3 2021 |
|---|---|---|---|---|
| Net Income | -$29.77M | -$12.96M | -$10.71M | -$3.90M |
| EPS Diluted | -$0.50 | -$0.24 | -$0.26 | -$0.10 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Acumen Pharmaceuticals, Inc. · CIK 1576885 · Engraved from SEC EDGAR